Chris Sweeney on treatment for M1 castration-sensitive/naive disease
Chris Sweeney presented, "Your Patient received ADT plus docetaxel for M1 castration-sensitive/naive disease- now what?", at the 2017 Advanced Prostate Cancer Consensus Conference (APCCC) in St. Gallen, Switzerland. Dr. Sweeney describes to Alicia Morgans the balancing act of the amount of treatment and the importance of the right treatment at the right time for the right patient without the biomarker we would like to have.
Christopher J. Sweeney, MBBS, is a Medical Oncologist at the Dana-Farber Cancer Institute. He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group, and the American Association for Cancer Research. Dr. Sweeney’s primary research interest is drug discovery and development. His academic focus is management of genitourinary malignancies, including prostate, bladder, testis and renal cell cancer.
- Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
- ECOG study E3805, a cooperative group trial: CHAARTED
Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer